Edelweiss recommended hold rating on Cipla with a target price of Rs 510 in its research report dated May 25, 2017.
CNBC-TV18's Ekta Batra lists out stocks that you should focus on.
Cipla Q4 net loss narrowed to Rs61.79 crore but muted EBITDA margins led to a downgrade by CLSA to underperform from outperform earlier.
Umang Vohra, MD and Global CEO of Cipla, said the company has always exited businesses where it is not best suited to play the game.
The consolidated earnings before interest, taxes, depreciation and amortisation (EBITDA) came in at Rs 506.2 crore against Rs 176.1 crore during March 2016 quarter.
Rajesh Agarwal of AUM Capital is of the view that one may hold Cipla.
Rajat Bose of rajatkbose.com advises buying Cipla at around Rs 400.
Meanwhile, the earnings before interest, taxes, depreciation and amortisation could come in at Rs 675.4 crore, while its operating margin is seen at 17.8 percent.
CNBC-TV18's Anisha Jain lists out stocks that you should focus on.
Individual news flow along with negative outlook for the sector by Credit Suisse hit the sector. Frontline stocks tank, pulling down the markets further.
Mitessh Thakkar of miteshthacker.com is of the view that one can sell Just Dial and Cipla.
Chandan Taparia of Motilal Oswal Securities recommends buying ITC, Petronet LNG and Cipla and suggests selling BPCL.
Jay Thakkar of Sharekhan advises buying Bliss GVS Pharma with a target of Rs 187.
Fourth quarter earnings, some big generic approvals in US, NPPA's notices to drug makers for non-compliance with pricing rules and GST rate announcement were the highlights of the week.
Mitessh Thakkar of miteshthacker.com is of the view that one can sell Cipla and buy Mangalore Refineries & Petrochemicals.
Sudarshan Sukhani of s2analytics.com suggests selling Kaveri Seed Company, Colgate Palmolive (India) and Cipla and advises buying Mahindra and Mahindra and DCB Bank.
According to Prakash Gaba of prakashgaba.com, Nifty has support at 9340 and resistance at 9500 while Bank Nifty has support at 22500 and resistance at 22850.
Here's what happened in pharma last week
According to Prakash Gaba of prakashgaba.com, Cipla may test Rs 576 while Rallis India may hit Rs 260.
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Infosys, Tata Consultancy Services, HCL Technologies and IRB Infrastructure and can sell Cipla.
Last week was all about fourth quarter results, debate over generic drugs and drug price control measures.
Prakash Gaba of prakashgaba.com is of the view that Nifty has support at 9300 and resistance at 9414 while Bank Nifty has support at 22100 and resistance at 22500.
Mitessh Thakkar of mitesshthakkar.com is of the view that one can buy Colgate Palmolive, Coffee Day, MMTC and Rolta India and sell Cipla.
Mitessh Thakkar of miteshthacker.com is of the view that one can buy Shipping Corporation of India and sell Cipla.
Sandeep Wagle of powermywealth.com is of the view that one can buy M&M Financial Services and sell Cipla while he feels that Reliance Industries may test Rs 2200 in 12-15 months.